Lophora Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Latest Deal Amount
  • $15M

  • Investors
  • 6

Lophora General Information

Description

Developer of next-generation neuroactive medicines designed to induce neuroplasticity and address unmet needs in neuropsychiatric disorders. The company offers an oral clinical-stage 5-HT2A therapy designed for at-home use, enabling neuropsychiatric patients to access treatments without the need for psychedelic-assisted treatment infrastructure.

Contact Information

Website
www.lophora.com
Formerly Known As
Lophora Pharma IVS, Lophora IVS
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Herlev Hovedhade 195A
  • Greater Copenhagen Area
  • 2730 Herlev
  • Denmark
+45 51
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Herlev Hovedhade 195A
  • Greater Copenhagen Area
  • 2730 Herlev
  • Denmark
+45 51

Lophora Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lophora Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 11-Aug-2026 $15M In Progress Clinical Trials - Phase 1
6. Later Stage VC 15-Jan-2025 Completed Clinical Trials - Phase 1
5. Later Stage VC 24-Aug-2023 Completed Pre-Clinical Trials
4. Seed Round 23-Nov-2020 Completed Startup
3. Accelerator/Incubator 03-Apr-2020 Completed Startup
2. Accelerator/Incubator 01-Jan-2019 $152K $152K Completed Startup
1. University Spin-Out 01-Jan-2018 Completed Startup
To view Lophora’s complete valuation and funding history, request access »

Lophora Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 1,046 $47 $47 1x $47 1.65%
Ordinary 2,519 $12.61 $12.61 1x $12.61 3.98%
To view Lophora’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Lophora Patents

Lophora Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7880894-B2 (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine acid addition salts, specific polymorphs thereof, and methods for producing them. Active 06-May-2021
JP-2024519457-A Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, certain polymorphs thereof and methods for preparing them Active 06-May-2021
CA-3216083-A1 Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, specific polymorphs thereof and methods for their manufactur Pending 06-May-2021
AU-2022270930-A1 Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, specific polymorphs thereof and methods for their manufacture Pending 06-May-2021
EP-4334288-A1 Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, specific polymorphs thereof and methods for their manufacture Pending 06-May-2021 C07D211/02
To view Lophora’s complete patent history, request access »

Lophora Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lophora Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
BNC Korea Corporation Minority
Mystic Ventures Venture Capital Minority
Innovationsfonden Accelerator/Incubator Minority
Novo Nordisk Corporation Minority
BioInnovation Institute Accelerator/Incubator Minority
You’re viewing 5 of 6 investors. Get the full list »

Lophora FAQs

  • When was Lophora founded?

    Lophora was founded in 2018.

  • Where is Lophora headquartered?

    Lophora is headquartered in Herlev, Denmark.

  • What is the size of Lophora?

    Lophora has 7 total employees.

  • What industry is Lophora in?

    Lophora’s primary industry is Drug Delivery.

  • Is Lophora a private or public company?

    Lophora is a Private company.

  • What is the current valuation of Lophora?

    The current valuation of Lophora is .

  • What is Lophora’s current revenue?

    The current revenue for Lophora is .

  • How much funding has Lophora raised over time?

    Lophora has raised $5.56M.

  • Who are Lophora’s investors?

    BNC Korea, Mystic Ventures, Innovationsfonden, Novo Nordisk, and BioInnovation Institute are 5 of 6 investors who have invested in Lophora.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process